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Environmental factors are determinant for the appearance of autoimmune thyroid dis-
eases (AITD) in susceptible subjects. Increased iodine intake, selenium, and vitamin D 
deficiency, exposure to radiation, from nuclear fallout or due to medical radiation, are 
environmental factors increasing AITD. Cigarette smoking is associated with Graves’ 
disease and Graves’ ophthalmopathy, while it decreases the risk of hypothyroidism and 
thyroid autoimmunity. Viral infections are important environmental factors in the patho-
genesis of AITD, too, particularly human parvovirus B19 (EVB19) and hepatitis C virus. 
Among the many chemical contaminants, halogenated organochlorines and pesticides 
variably disrupt thyroid function. Polychlorinated biphenyls and their metabolites and 
polybrominated diethyl ethers bind to thyroid transport proteins, such as transthyre-
tin, displace thyroxine, and disrupt thyroid function. Among drugs, interferon- and 
iodine-containing drugs have been associated with AITD. Moreover intestinal dysbiosis 
causes autoimmune thyroiditis. To reduce the risk to populations and also in each 
patient, it is necessary to comprehend the association between environmental agents 
and thyroid dysfunction.
Keywords: autoimmune thyroid diseases, genetic influences, environmental influences, thyroid cancer, antithyroid 
antibodies
inTRODUCTiOn
Graves’ disease (GD) and Hashimoto’s thyroiditis (HT) are the principal clinical presentations of 
autoimmune thyroid diseases (AITD), characterized by lymphocytic infiltration of the thyroid 
parenchyma, and clinically by thyrotoxicosis and hypothyroidism, respectively. AITD lead to an 
immune attack on the thyroid, whose mechanisms are still unclear. Genetic susceptibility and 
environmental triggers interact as the principal active part toward the development of the disease.
Autoimmune thyroid diseases prevalence is about 5% (1, 2) while that of antithyroid antibodies 
(ATAs) without clinical disease could be higher (3).
Abbreviations: AITD, autoimmune thyroid diseases; GD, Graves’ disease; HT, Hashimoto’s thyroiditis; ATA, antithyroid 
antibodies; TPOAb, thyroid peroxidase antibodies; GO, Graves’ ophthalmopathy; TgAb, thyroglobulin antibodies; AT, autoim-
mune thyroiditis; TSH, thyroid-stimulating hormone; HIV, human immunodeficiency virus; HCV, hepatitis C virus; EVB19, 
erythrovirus B19; TC, thyroid cancer; PTC, papillary thyroid cancer; CHC, chronic hepatitis C; MC, mixed cryoglobulinemia; 
IFN, interferon; AIH, amiodarone-induced hypothyroidism; AIT, amiodarone-induced thyrotoxicosis; PCB, polychlorinated 
biphenyl; T3, triiodothyronine; T4, thyroxine; Cd, cadmium; Mn, manganese.
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enDOGenOUS FACTORS ASSOCiATeD 
wiTH AiTD
Autoimmune thyroid diseases commonly affect more fre-
quently females than males, such as in many other autoimmune 
diseases (4).
This is probably due to differences between male and female 
immune systems (5), which are present in many animal species; 
in fact, males have immune suppression versus females, which is 
linked to male sexual activity (6). Females show greater immune 
reactivity (7), and this increased immunocompetence might 
translate to greater resilience to infectious and non-infectious 
disorders.
In females, the immunological changes during pregnancy and 
their regression in the postpartum period are determinant, even if 
the predisposition of females to AITD is observed in nulliparous 
women, too. Microchimerism (i.e., the presence of small popula-
tions of cells from one subject in another genetically distinct one) 
is an endogenous factor associated with AITD (8).
Antithyroid antibodies frequency has a peak around 
45–55 years, and hypothyroidism due to HT is more frequent in 
advanced age.
The HT prevalence and that of ATAs differ among races (8–10).
Incidence of HT shows an elevated geographic variability. 
However, worldwide, the current incidence rates of hypothyroid-
ism and HT are higher than previously in similar regions (11); 
it is unclear whether this depends on the use of more accurate 
diagnostic procedures or actual increased incidence per se (12).
GeneTiC SUSCePTiBiLiTY
The importance of genetic susceptibility has been suggested by 
the familial clustering of AITD (20–30% in siblings of affected 
subjects, with a sibling risk ratio of approximately 17; high preva-
lence of ATA (about 50%) in siblings of AITD patients) (13). The 
concordance rate of monozygotic twin studies is ranging from 
0.3 to 0.6 versus 0.00–0.1 for dizygotic twins (8, 14); heritability 
of ATA is 70%, of GD 79% (8).
Among genes linked to AITD and/or the presence of ATA 
(15, 16), whose function is known, 7 out of 11 take part in T cells 
function, leading to hypothesize that T lymphocytes are impor-
tant in the pathogenesis of AITD.
enviROnMenTAL FACTORS
Environmental factors influence the occurrence of AITD of 
approximately 20%, as they are associated with the activation of 
innate immune response and AITD development in susceptible 
individuals (17, 18).
external Radiation
The prevalence of ATA increased in children and adolescents 
exposed to radiations about 6–8 years after the Chernobyl acci-
dent. Thyroid peroxidase antibodies (TPOAb) prevalence was 
higher in radiation-exposed Belarusian children (6.4 versus 2.4% 
in not exposed) and in adolescents exposed to radioactive fallout 
13–15 years after the Chernobyl accident (19). The radiation dose 
was related to increased TPOAb prevalence, thereby suggesting 
that important clinical changes could appear gradually (20). The 
onset of GD, and even of Graves’ ophthalmopathy (GO), may 
occur after radioiodine treatment of toxic goiter (21). Thyroid 
ionizing radiation exposure was related with the occurrence of 
tardive hypothyroidism, thyroid nodules, or cancer, and even 
acute thyroiditis (22, 23).
iodine
Iodine is essential for thyroid function. Constant iodine 
prophylaxis and increased iodine intake gradually reduce 
iodine deficiency-related thyroid disorders (24). In the Danish 
population, a 53% higher incidence of spontaneous overt hypo-
thyroidism (probably autoimmune) was observed in mild, than 
in moderate, iodine deficiency (25). Iodine excess, owing to a 
great environmental iodine exposure besides poor monitoring, is 
a precipitating environmental factor in the development of AITD. 
Excessive amounts of iodide have been associated with the onset 
of autoimmune thyroiditis (AT) (26).
Selenium
Selenium, whose necessary intake ranges from 60 to 75 μg/day, 
exerts an influence on immunological responses, cell growth, 
and viral defense and is necessary for normal thyroid function 
and homeostasis in humans. Selenium is essential for the activity 
of enzymes, such as glutathione peroxidases, deiodinases, and 
thioredoxin reductases, and for the synthesis and function of 
thyroid hormones and protects cells against free radicals and 
oxidative damage. A low selenium concentration is associated 
with the appearance of AT or GD (27). As selenium is involved 
in regulation of cell cycle, a decreased concentration is also 
important in the development of thyroid cancer (TC) (28, 29). 
In a cross-sectional observational study in Shaanxi Province 
(China), the relationship between selenium status, dietary fac-
tors, and pathological thyroid conditions was investigated. In 
the adequate-selenium county, the prevalence of pathological 
thyroid disorders (subclinical hypothyroidism, hypothyroidism, 
AT, and enlarged thyroid) was significantly lower than in the 
low-selenium county (18.0 versus 30.5%; P <  0.001). Elevated 
circulating selenium level was associated with reduced odds ratio 
(95% confidence interval) of subclinical hypothyroidism (0.68; 
0.58, 0.93), hypothyroidism (0.75; 0.63, 0.90), AT (0.47; 0.35, 
0.65), and enlarged thyroid (0.75; 0.59, 0.97) (30).
A paper (31) evaluated the real efficacy of selenium sup-
plementation in HT, measuring thyroid-stimulating hormone 
(TSH), thyroid hormones, TPOAb and thyroglobulin antibod-
ies (TgAb) levels, and thyroid echogenicity after 6  months of 
l-selenomethionine treatment. The authors concluded that the 
short-term l-selenomethionine supplementation has a restricted 
impact on the natural course in euthyroid HT.
Smoking
The data about the effect of smoking on ATA (TgAb and TPOAb) 
and chronic AT (32, 33) are conflicting.
A meta-analysis reported the association of smoking with 
HT and postpartum thyroid dysfunction (34). By contrast, a 
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prospective cohort study demonstrated, in subjects at risk of 
developing AITD, that smoking was negatively associated with 
the presence of TPOAb (35, 36), which was confirmed in popula-
tion studies (37–40). Smoking during pregnancy was inversely 
correlated with the risk of thyroiditis, while it raised the preva-
lence of postpartum thyroiditis (41).
On the whole, smoking decreases the risk of appearance of 
TPOAb and TgAb and autoimmune hypothyroidism of approxi-
mately 40%; this protective effect disappears few years after cessa-
tion. It has been suggested that while activating nicotine receptors 
on immune cells, the autoimmune profile moves away from Th1 
and Th17 responses (42, 43).
The proportion of smoking people was more elevated in 
patients with severe ophthalmopathy (64.2% in GO and 47.9% 
in GD versus 30% in control subjects) (32, 44–47). Smoking is 
related to an increased risk of Graves’ hyperthyroidism (twofold), 
GO (three to four times), or relapse of GD or GO (48, 49), and it 
is linked to a more severe GO. Many different hypotheses about 
how smoking may enhance the risk of GD or GO have been 
reported (50–58).
viruses
Viruses activate the adaptive and innate immunity and might cause 
HT. Human T-cell lymphotropic virus-1, herpes simplex virus, 
rubella, mumps virus, Epstein–Barr virus, enterovirus in HT, 
retroviruses [human T-cell lymphotropic virus-1, human foamy 
virus or human immunodeficiency virus (HIV), and Simian virus 
40] in GD have been shown (59). Acquired immunodeficiency 
syndrome and HIV have been associated with various thyroid 
diseases (60). Hepatitis C virus (HCV) and human parvovirus 
B19 (EVB19) are candidate viruses for AITD (59, 61).
Parvovirus B19
EVB19 DNA was detected in about 12% of HT cases versus 3% 
controls (P < 0.03), suggesting that acute EVB19 infection could 
be associated with the appearance of AT (62, 63).
In slides of paraffin-embedded thyroid tissues from 112 
patients undergoing thyroidectomy, EVB19 DNA was revealed 
in thyrocytes (or in lymphocytes), particularly in papillary TC 
(PTC), leading to hypothesize that EVB19 is implicated in thyroid 
carcinogenesis (64). In another study, EVB19 was present in 88% 
PTC tumors (65).
EVB19 was present in thyrocytes in patients with multinodu-
lar goiters, thyroiditis, or GD, by immunohistochemistry, PCR or 
in situ hybridization (66, 67). In addition, in primary thyrocytes, 
after EVB19 NS1 transfection, positive regulatory domain zinc 
finger protein 1 upregulation was observed (68).
The relationship between EVB19 and different thyroid disor-
ders needs to be investigated (69).
Chronic HCv infection and Thyroid
Viral replication occurs in hepatocytes and also in extrahe-
patic tissues and peripheral blood mononuclear cells (70, 71). 
Extrahepatic manifestations (72, 73) [mixed cryoglobulinemia 
(MC), endocrinological diseases (AITD and type 2 diabetes), 
Sjogren’s syndrome] are present in about 38–76% patients with 
chronic hepatitis C (CHC). HCV interferes with functions and 
self-recognition mechanisms (in immune system or in thyrocytes) 
leading to destruction of thyroid and beginning the autoimmune 
disease (74).
The association between HCV infection and thyroid autoim-
munity has been shown (75–82). Thyroid disorders frequency 
in interferon (IFN)-free HCV subjects is approximately 10–15% 
(83–89). Thyroid autoimmune abnormalities frequency was also 
significantly increased in MC +  HCV patients versus controls 
(AT 35 versus 16%; subclinical hypothyroidism, 11 versus 2%).
In female patients with MC + HCV, or CHC, thyroid disorders 
were represented by higher risk for AT and hypothyroidism and 
elevated circulating TPOAb (88, 90).
An increased prevalence of PTC has been shown in CHC, with 
or without MC, overall when AT was present (91–97), suggesting 
that AT might be a predisposing condition for TC (95–97). An 
elevated mortality for TC in HCV patients (98) has been shown, 
suggesting that it impacts survival of these patients, and giving 
the advice of a careful thyroid monitoring in HCV patients in 
presence of thyroid nodules. HCV thyroid infection upregulates 
CXCL10 expression and secretion of thyroid cells, recruiting 
other Th1 lymphocytes into the gland, leading to the appearance 
of AITD in predisposed individuals (99, 100). A careful thyroid 
function and nodules follow-up in subjects showing risk factors 
(female gender, a border line high initial TSH, TPOAb+, a small 
and hypoechoic thyroid) for the appearance of AITD in HCV and 
MC + HCV should be performed.
Drugs
Among drugs, IFN- and iodine-containing drugs have been 
associated with AITD. The “de novo” presence of ATA and overt 
dysfunctions in euthyroidism have been reported upon IFN-α 
therapy, suggesting that it can exacerbate or induce latent thyroid 
disorders, inducing AITD (74). The standard dual therapy with 
pegylated IFN-α/ribavirin has been substituted by a triple therapy 
with new direct-acting antiviral drugs (NS3/4A serine protease 
inhibitor) (74) (with/without ribavirin), thereby ameliorating the 
patient compliance and decreasing the risk for thyroid autoim-
munity (74).
Drugs containing iodide may induce hypothyroidism in 
euthyroid HT patients, 131-I or surgically treated GD, or follow-
ing hemithyroidectomy for nodules. Medications can also induce 
hyperthyroidism in patients with endemic iodine-deficient goiter, 
autonomous nodules, or non-toxic nodular goiter, or in patients 
recently treated with antithyroid drugs for GD. Rarely, hypo-
thyroidism or hyperthyroidism occur in patients with normal 
thyroid function in therapy with iodide. The etiology of hypothy-
roidism and goiter induced by iodide is not clear in patients with 
cystic fibrosis. Iodine-induced hypothyroidism might appear in 
patients treated with drugs altering thyroid function (lithium, 
phenazone, sulfisoxazole, etc.) (101). Amiodarone (for treatment 
of cardiac arrhythmias) has serious adverse effects on the thyroid 
function. Amiodarone has similar structure to thyroid hormones, 
for example, the iodine moieties on the inner benzene ring, and it 
might cause thyroid dysfunction. Thyroid dysfunctions induced 
by amiodarone are “amiodarone-induced thyrotoxicosis” (AIT; 
usually in iodine-deficient areas) and “amiodarone-induced 
hypothyroidism” (AIH; commonly in iodine-sufficient areas). 
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The type 1 AIT is commonly present in patients with previous 
thyroid dysfunctions or goiter, while type 2 AIT in normal 
thyroid and leads to destructive thyroiditis. Patients treated with 
amiodarone should be controlled for the presence of thyroid 
dysfunctions. When monitoring patients, initial tests should 
include TSH, thyroxine (T4), triiodothyronine (T3), and ATA. 
The treatment depends on the type of AIT, including thionamides 
and/or glucocorticoids. AIH responds positively to thyroxine 
replacement therapy (102–104).
Microbiota
As intestinal dysbiosis occurs, the epithelial barrier fails to 
function and there is the appearance of intestinal and systemic 
disorders. The intestinal tract is determinant in metabolizing 
nutrients, drugs, and hormones, exogenous and endogenous 
iodothyronines, and micronutrients implicated in thyroid 
homeostasis. Different autoimmune disorders have a pathoge-
netic link with dysbiosis, not yet clarified in AITD. It has been 
hypothesized that intestinal dysbiosis may cause AT. Hyper- and 
hypothyroidism, frequently in AITD, are associated with bacte-
rial overgrowth in small intestinal or with changes in composi-
tion of microbiota (105).
vitamin D
Vitamin D is responsible for anti-inflammatory and immu-
noregulatory effects (106). Different autoimmune diseases show 
low vitamin D levels, which are also associated with ATA, altered 
thyroid function, high thyroid volume, elevated TSH levels, and 
adverse pregnancy outcome in AITD women. Vitamin D binds 
to its receptor, harbored on many human immune cells, and 
modulates immune cells activity, provoking innate and adaptive 
immune responses. Vitamin D receptor gene polymorphisms 
are associated with AITD, and vitamin D deficiency is linked to 
AITD through gene polymorphism (in particular BsmI and TaqI 
polymorphism) or environmental factors (lack of dietary uptake 
and sun exposure) (107). A study evaluated the association 
between vitamin D levels and AITD through systematic literature 
review, suggesting that low levels of serum 25(OH)D was related 
to AITD (108, 109).
Chemicals
Long-term human studies on the effects of environmental chemi-
cals on thyroid-related outcomes such as growth and develop-
ment are still lacking. The human exposure scenario with lifelong 
exposure to a vast mixture of chemicals in low doses and the 
large physiological variation in thyroid hormone levels between 
individuals render human studies very difficult. Polychlorinated 
biphenyls (PCBs) have thyroid-disrupting effects, and it is 
suggested that also bisphenol A, phthalates, brominated flame 
retardants, and perfluorinated chemicals show thyroid-disrupting 
characteristics (110, 111). PCBs, or other persistent organochlo-
rine compounds, disrupt thyroid hormone homeostasis, as shown 
by animal studies, while dietary exposure to PCBs affects serum 
thyroid hormones and TSH in human subjects. A study reviewed 
available epidemiologic studies within this field, reporting dis-
cordant results between studies of correlations, and suggesting 
that there are no clear interstudy dose–response associations. 
However, current data do not exclude such associations (112). 
Among the considered studies by a systematic analysis of associa-
tions between PCB exposure and thyroid hormones or TSH in 
pregnant women and newborns, only one showed a significant 
association between PCBs and total T3 levels, but no association 
was evidenced assessing thyroid function by serum TSH and free 
T4 (113, 114).
Heavy Metals
Cadmium (Cd) is considered a category I carcinogen (on lungs, 
testicles, and prostate). Cd accumulates in liver, pancreas, kidneys, 
and also in the thyroid. Cd in blood correlates with concentra-
tions in the thyroid. Cd blood and urine levels are more elevated 
in women in fertile age, than in men. Mitochondria are the main 
intracellular targets for Cd. In chronic Cd toxicity, multinodular 
goiter, thyroglobulin hyposecretion, and parafollicular cell hyper-
plasia are frequent (115).
Manganese (Mn) is toxic at high levels. Oxidoreductases, 
transferases, hydrolases, lyases, isomerases, ligases, glutamine 
synthetase, and Mn superoxide dismutase are Mn-containing 
enzymes. Mn superoxide dismutase is the main antioxidant 
enzyme able to neutralize the toxic effects of reactive oxygen 
species. Environmental or occupational exposure to high levels 
of Mn causes a neuropathy similar to idiopathic Parkinson’s 
disease, known as manganism. Dopamine and its metabolites are 
altered in manganism and Parkinson’s disease, as they are able 
to inhibit TSH secretion. Dopamine and dopaminergic receptors 
are involved in neurodevelopment and TSH modulation. This 
suggests that excessive Mn exposure during gestation is linked to 
altered neurodevelopmental outcomes, due to a dysregulation of 
dopaminergic control of TSH on thyroid hormones levels (116).
Thyroid cancer incidence is markedly increased in volcanic 
areas. In the volcanic area of Mt. Etna in Sicily, a non-anthro-
pogenic pollution with heavy metals has been documented, 
a consequence of gas, ash, and lava emission. Soil, water, and 
atmosphere contamination, via the food chain, biocontaminate 
the residents as documented by high levels in the urines and 
the scalp hair compared to individuals living in adjacent non-
volcanic areas. Trace amounts of metals are essential nutrients 
but, at higher concentrations, can be toxic for living cells. 
Metals can behave both as endocrine disruptors, perturbing the 
hormonal system, and as carcinogens, promoting malignant 
transformation. Similar to other carcinogens, the transforming 
effect of heavy metals is higher in developing organisms, such as 
the fetus (contaminated via the mother), and individuals in early 
childhood. The metal concentration in tissues has been rarely 
measured in the thyroid (117).
COnCLUSiOn
Although the genetic background accounts for approximately 70% 
of the risk for developing AITD, environmental triggers have an 
important role in the AITD development in susceptible individu-
als. Radiation exposure, and increased iodine intake, selenium, 
and vitamin D deficiency are environmental factors increasing 
the AITD risk. GO and GD are associated with cigarette smoke 
(50, 118), while it seems to decrease the risk of hypothyroidism 
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and prevalence of thyroid antibodies (42, 43). Viral infections 
are a determinant environmental factor in AITD pathogenesis 
(1, 10). Among the many chemical contaminants, halogenated 
organochlorines and pesticides variably disrupt thyroid func-
tion. PCBs and their metabolites and polybrominated diethyl 
ethers, bind to thyroid transport proteins, such as transthyretin, 
displace thyroxine, and disrupt thyroid function. Meanwhile, at 
the molecular level, PCB congeners may result in inhibition of the 
natrium/iodide symporter (119). Among drugs, IFN- and iodine-
containing drugs have been associated with AITD. Moreover, it 
seems that intestinal dysbiosis triggers AT (105). To reduce the 
risk to populations but also in each patient, it is necessary to 
comprehend the association between environmental agents and 
thyroid dysfunction. These factors are considerable for those 
subjects who are at increased risk of AITD according to their 
family history (120).
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